The gross margin expansion suggests AMN is capturing better bill-pay spreads, but the operating margin of 4.0% in Q2 2026, though up from -18.8% a year earlier, remains far below the 8.5% seen in Q1 2026. This implies that SG&A costs, while reduced, are still absorbing most of the gross profit gains. The negative net margin of -3.5% on a TTM basis, despite the positive quarterly net margin, points to lingering impairment or restructuring charges that continue to weigh on reported profitability. Investors should monitor whether the operating margin can sustainably exceed the 5% threshold, as that would signal genuine operating leverage rather than one-off cost savings.

The improvement in ROIC from -7.9% to 1.9% over the last six quarters is encouraging, but the absolute level remains inadequate for a company with a debt-to-equity ratio above 1.0. The negative ROE of -23.5% in Q4 2024 and -17.6% in Q2 2025 highlight the severe earnings destruction during the downturn, and the recent 2.9% ROE in Q2 2026 is still far below the 29.5% ROE of peer Chemed. This suggests that AMN's asset base, including $759 million of goodwill, is not yet generating sufficient returns to justify its carrying value. The path to double-digit ROIC likely requires both margin recovery and continued deleveraging, but the current trajectory suggests a slow grind rather than a sharp rebound.

The improvement in DSO from 79 to 56 days over the past six quarters indicates better receivables collection, likely due to tighter credit management. However, the negative DPO (e.g., -38 days in Q2 2026) suggests AMN is paying suppliers faster than it collects from customers, which is unusual for a staffing firm and may indicate a strategic shift to secure clinician supply. The cash conversion cycle is not calculable due to missing DIO data, but the working capital swings in the cash flow statement—such as the $624.5 million reversal between Q1 and Q2 2026—highlight the inherent volatility in this business. This volatility makes quarterly efficiency ratios unreliable for trend analysis, and investors should focus on annualized working capital metrics to gauge true operational efficiency.

AMN has reduced total debt from $1.3 billion to $775.8 million over the past two years, a clear deleveraging trend that strengthens the balance sheet. However, the interest coverage ratio of 3.84x in Q2 2026, while up from 0.66x in Q4 2025, is still modest and would be strained if operating income reverts to the negative levels seen in 2025. The D/EBITDA ratio of 13.26x in Q2 2026 is elevated, though it reflects the depressed EBITDA base; the forward EV/EBITDA of 6.50x suggests the market expects EBITDA to recover. The company's ability to service debt appears manageable in the near term, but the thin coverage warrants monitoring, especially if the recovery in operating margins stalls.

The improvement in the current ratio from 0.94 to 1.13, driven by a surge in cash from $34 million to $361.8 million, provides a stronger liquidity buffer than in recent quarters. However, the quick ratio is identical to the current ratio, reflecting the absence of inventory, which is typical for a service business. The liquidity position appears adequate for normal operations, but the negative FCF margin of -29.5% in Q2 2026 and the volatile working capital patterns suggest that cash flows can swing dramatically. Under a severe stress scenario, such as a renewed drop in demand, the current ratio could quickly deteriorate, as seen in Q4 2025 when it fell below 1.0. Investors should monitor whether the cash balance remains elevated or if it is used for debt repayment or acquisitions.